CA2184385A1 - Composition pour le traitement de maladies pulmonaires - Google Patents

Composition pour le traitement de maladies pulmonaires

Info

Publication number
CA2184385A1
CA2184385A1 CA002184385A CA2184385A CA2184385A1 CA 2184385 A1 CA2184385 A1 CA 2184385A1 CA 002184385 A CA002184385 A CA 002184385A CA 2184385 A CA2184385 A CA 2184385A CA 2184385 A1 CA2184385 A1 CA 2184385A1
Authority
CA
Canada
Prior art keywords
hydrogen
6alkyl
3alkyl
compound
found
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002184385A
Other languages
English (en)
Inventor
Philip Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2184385A1 publication Critical patent/CA2184385A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne des compositions pharmaceutiques destinées au traitement de la pneumopathie et plus particulièrement de la mucoviscidose, ces compositions comprenant une azétidinone substituée de formule (I) dont on a découvert le rôle d'inhibiteur puissant de l'élastase, et une protéine raccourcissant la (F)-actine, telle que la gelsoline.
CA002184385A 1994-03-11 1995-03-07 Composition pour le traitement de maladies pulmonaires Abandoned CA2184385A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21242094A 1994-03-11 1994-03-11
US212,420 1994-03-11

Publications (1)

Publication Number Publication Date
CA2184385A1 true CA2184385A1 (fr) 1995-09-14

Family

ID=22790936

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002184385A Abandoned CA2184385A1 (fr) 1994-03-11 1995-03-07 Composition pour le traitement de maladies pulmonaires

Country Status (5)

Country Link
EP (1) EP0755262A4 (fr)
JP (1) JPH09510212A (fr)
AU (1) AU686780B2 (fr)
CA (1) CA2184385A1 (fr)
WO (1) WO1995024207A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1755661T3 (da) * 2004-05-12 2014-06-16 Brigham & Womens Hospital Gelsolin til anvendelse til behandling af infektioner
ES2641879T3 (es) 2006-03-15 2017-11-14 The Brigham And Women's Hospital, Inc. Uso de gelsolina para diagnosticar y tratar enfermedades inflamatorias
CN112399860A (zh) 2018-06-06 2021-02-23 麻省理工学院 用于在真核细胞中翻译的环状rna
WO2020237227A1 (fr) 2019-05-22 2020-11-26 Massachusetts Institute Of Technology Compositions et procédés d'arn circulaire
EP4289951A3 (fr) 2019-12-04 2024-03-13 Orna Therapeutics, Inc. Méthodes et compositions d'arn circulaire

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
ATE171625T1 (de) * 1990-04-11 1998-10-15 Brigham & Womens Hospital Therapeutische verwendung von actin-bindenden verbindungen
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
US5276139A (en) * 1991-08-26 1994-01-04 Merck & Co., Inc. Haptens useful in evaluating inhibition of PNN elastase by N-substituted azetidinones

Also Published As

Publication number Publication date
WO1995024207A1 (fr) 1995-09-14
AU686780B2 (en) 1998-02-12
JPH09510212A (ja) 1997-10-14
AU2099495A (en) 1995-09-25
EP0755262A4 (fr) 1997-05-07
EP0755262A1 (fr) 1997-01-29

Similar Documents

Publication Publication Date Title
AU756150B2 (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor
AU698705B2 (en) Thrombin inhibitors
AU764334B2 (en) Dipeptide nitrile Cathepsin K inhibitors
KR101321257B1 (ko) 브라디키닌 길항물질인 신규 벤즈아미드 유도체
LV13338B (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
EP1156045A1 (fr) Derives d'amides et compositions de medicaments
NZ515217A (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor
DE19620041A1 (de) Adhäsionsrezeptor-Antagonisten
SK61399A3 (en) HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa
BG105788A (bg) Сулфамато хидроксамова киселина като металопротеазен инхибитор
DE69921994T2 (de) Heterozyklische verbindungen mit faktor xa hemmender wirkung
JP2001508757A (ja) フィブリノーゲンレセプターアンタゴニスト
EP0796271B1 (fr) p-amidinobenzylamides dipeptidiques a restes n-terminaux sulfonyle ou aminosulfonyle
JP2020158522A (ja) トロンビン阻害剤としてのハロゲノピラゾール
DE10029014A1 (de) Urokinase-Hemmstoffe
WO1999054321A1 (fr) Diamines substituees et leur utilisation en tant qu'inhibiteurs d'adhesion cellulaire
JP2001521522A (ja) 新規なハロ−アルコキシカルボニルプロドラッグ
CA2184385A1 (fr) Composition pour le traitement de maladies pulmonaires
US5747485A (en) Substituted azetidiones as anti-inflammatory and antidegenerative agents
US5591737A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
EP2953932B1 (fr) Dérivés d'acide carboxylique substitués à titre d'inhibiteurs d'aggrécanase pour traiter l'arthrose
DE19713000A1 (de) Adhäsionsrezeptor-Antagonisten
WO1999048911A1 (fr) Monobactams inhibiteurs d'enzymes
ZA200405802B (en) Heterocyclic compounds having elastase-inhibitory activity and intermediates thereof.
US7084134B2 (en) Thrombin inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued